1013 related articles for article (PubMed ID: 2438781)
21. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
22. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of CHOP and COP-BLAM chemotherapy in highly malignant non-Hodgkin's lymphoma].
Gerhartz HH; Thiel E; Hiller E; Nerl C; Wilmanns W; Huhn D
Dtsch Med Wochenschr; 1986 Oct; 111(40):1511-5. PubMed ID: 2428572
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Fisher RI
Cancer Chemother Pharmacol; 1997; 40 Suppl():S42-6. PubMed ID: 9272133
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
26. CHOP versus m-BACOD in non-Hodgkin's lymphoma.
Hryniuk W
N Engl J Med; 1993 Feb; 328(8):581. PubMed ID: 7678920
[No Abstract] [Full Text] [Related]
27. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens.
Shapiro CL; Yeap BY; Godleski J; Jochelson MS; Shipp MA; Skarin AT; Canellos GP
Cancer; 1991 Aug; 68(4):699-705. PubMed ID: 1713121
[TBL] [Abstract][Full Text] [Related]
28. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
[TBL] [Abstract][Full Text] [Related]
29. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
O'Reilly SE; Hoskins P; Klimo P; Connors JM
Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
[TBL] [Abstract][Full Text] [Related]
30. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.
Shipp MA; Yeap BY; Harrington DP; Klatt MM; Pinkus GS; Jochelson MS; Rosenthal DS; Skarin AT; Canellos GP
J Clin Oncol; 1990 Jan; 8(1):84-93. PubMed ID: 1688615
[TBL] [Abstract][Full Text] [Related]
31. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher RI; DeVita VT; Hubbard SM; Longo DL; Wesley R; Chabner BA; Young RC
Ann Intern Med; 1983 Mar; 98(3):304-9. PubMed ID: 6600902
[TBL] [Abstract][Full Text] [Related]
32. [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas].
Avilés A; Huerta J; Guzmán R; Zepeda G; Díaz-Maqueo JC
Rev Invest Clin; 1990; 42(4):271-6. PubMed ID: 1708910
[TBL] [Abstract][Full Text] [Related]
33. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
34. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
35. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG).
Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L
Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334
[TBL] [Abstract][Full Text] [Related]
36. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
37. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas.
Cassi E; Butti C; Baldini L; Pisoni GB; Ceriani A; Confalonieri C; Scandolaro L; De Paoli A; Lombardi F; Montalbetti L
Leuk Lymphoma; 1994 Mar; 13(1-2):111-8. PubMed ID: 7517742
[TBL] [Abstract][Full Text] [Related]
38. [A comparative study of CHOP therapy and COP-BLAM therapy for non-Hodgkin's lymphoma in elderly patients].
Arai N; Hara A; Kaneko H; Umeda M; Shirai T
Nihon Ronen Igakkai Zasshi; 1991 Sep; 28(5):672-7. PubMed ID: 1721658
[TBL] [Abstract][Full Text] [Related]
39. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.
Canellos GP; Skarin AT; Klatt MM; Rosenthal DS; Case DC; Pinkus GS; Jochelson MS; Yeap BY; Shipp MA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777
[TBL] [Abstract][Full Text] [Related]
40. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]